BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SCYNEXIS, Inc. and Immune Design Corporation Collaborate on Innovative Process for Vaccine Production Technology


4/10/2013 11:33:17 AM

RESEARCH TRIANGLE PARK, NC--(Marketwired - April 10, 2013) - SCYNEXIS, Inc. announced today that Immune Design Corp. has selected SCYNEXIS as its chemical development and cGMP production partner for manufacture of Glucopyranosyl Lipid A (GLA).

Immune Design's GLA is the first clinical stage synthetic TLR4 agonist with the demonstrated ability to enhance vaccine immunogenicity in humans. Clinical and preclinical studies have established that GLA has properties that may make it ideal for use as an adjuvant for prophylactic and therapeutic vaccines.

By joining forces, the teams have accomplished a major breakthrough, validating a new synthesis for GLA, within a short period of time.

"Partnering with SCYNEXIS, with its efficient and cost-effective chemistry synthesis process, moves us closer to delivering important vaccine products to those in need," said Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design.

"We're excited that our talented team provided the expertise and inventiveness, in partnership with Immune Design, to deliver this important compound," said Yves Ribeill, Ph.D., President and Chief Executive Officer of SCYNEXIS. "At SCYNEXIS, we always welcome the opportunity to join forces and solve the challenges of complex chemistry projects while creating innovative solutions with our partners."

SCYNEXIS' contract research and development services include Integrated Pharmaceutical Solutions, Discovery Research and Integrated Parasitology.

About Immune Design Corporation
Immune Design is a privately held, clinical-stage biotechnology company based in Seattle, Washington, and formed in 2008 to bring together some of the world's leaders in the field of molecular immunology to develop vaccines for the treatment and prevention of infectious and malignant disease. The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response. This goal is accomplished through the application of two proprietary technology platforms that activate the immune system by distinct mechanisms. Additional information can be found on the company's website at www.immunedesign.com.

About SCYNEXIS
SCYNEXIS delivers innovative solutions to solve the toughest problems in drug discovery and development for our pharmaceutical, global health and life science partners. We have successfully delivered preclinical and clinical drug candidates to our customers across all major therapeutic indications and have developed our own proprietary cyclophilin inhibitor programs for the treatment of a broad range of diseases, including HCV, HBV and inflammation. Founded in 2000, SCYNEXIS is located in Research Triangle Park, North Carolina. Visit www.scynexis.com.


Immune Design Media Contact:
Paul Rickey
media@immunedesign.com
Tel. + 1-206-826-7904

SCYNEXIS Media Contacts:
Alissa Maupin
SCYNEXIS
Alissa.Mupin@scynexis.com
Tel. + 1-919-206-7246

Rick Rountree
Rountree Communications, Inc.
rick@rickrountree.com
Tel. + 1-919-878-1144



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES